These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

321 related articles for article (PubMed ID: 21474670)

  • 21. Reelin promotes the adhesion and drug resistance of multiple myeloma cells via integrin β1 signaling and STAT3.
    Lin L; Yan F; Zhao D; Lv M; Liang X; Dai H; Qin X; Zhang Y; Hao J; Sun X; Yin Y; Huang X; Zhang J; Lu J; Ge Q
    Oncotarget; 2016 Mar; 7(9):9844-58. PubMed ID: 26848618
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Integrin β5 contributes to the tumorigenic potential of breast cancer cells through the Src-FAK and MEK-ERK signaling pathways.
    Bianchi-Smiraglia A; Paesante S; Bakin AV
    Oncogene; 2013 Jun; 32(25):3049-58. PubMed ID: 22824793
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Integrin alpha4beta1 involvement in stromal cell-derived factor-1alpha-promoted myeloma cell transendothelial migration and adhesion: role of cAMP and the actin cytoskeleton in adhesion.
    Parmo-Cabañas M; Bartolomé RA; Wright N; Hidalgo A; Drager AM; Teixidó J
    Exp Cell Res; 2004 Apr; 294(2):571-80. PubMed ID: 15023543
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Chemokine stromal cell-derived factor-1alpha modulates VLA-4 integrin-mediated multiple myeloma cell adhesion to CS-1/fibronectin and VCAM-1.
    Sanz-Rodríguez F; Hidalgo A; Teixidó J
    Blood; 2001 Jan; 97(2):346-51. PubMed ID: 11154207
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A novel carbohydrate-based therapeutic GCS-100 overcomes bortezomib resistance and enhances dexamethasone-induced apoptosis in multiple myeloma cells.
    Chauhan D; Li G; Podar K; Hideshima T; Neri P; He D; Mitsiades N; Richardson P; Chang Y; Schindler J; Carver B; Anderson KC
    Cancer Res; 2005 Sep; 65(18):8350-8. PubMed ID: 16166312
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cell adhesion mediated drug resistance (CAM-DR): role of integrins and resistance to apoptosis in human myeloma cell lines.
    Damiano JS; Cress AE; Hazlehurst LA; Shtil AA; Dalton WS
    Blood; 1999 Mar; 93(5):1658-67. PubMed ID: 10029595
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Upregulated expression and function of the α4β1 integrin in multiple myeloma cells resistant to bortezomib.
    Sevilla-Movilla S; Arellano-Sánchez N; Martínez-Moreno M; Gajate C; Sánchez-Vencells A; Valcárcel LV; Agirre X; Valeri A; Martínez-López J; Prósper F; Mollinedo F; Teixidó J
    J Pathol; 2020 Sep; 252(1):29-40. PubMed ID: 32501543
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Vascular endothelial growth factor C enhances cervical cancer migration and invasion via activation of focal adhesion kinase.
    Chen H; Suo K; Cheng Y; Zheng B; Xu L
    Gynecol Endocrinol; 2013 Jan; 29(1):20-4. PubMed ID: 22817694
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Toll-like receptor (TLR)-1/2 triggering of multiple myeloma cells modulates their adhesion to bone marrow stromal cells and enhances bortezomib-induced apoptosis.
    Abdi J; Mutis T; Garssen J; Redegeld FA
    PLoS One; 2014; 9(5):e96608. PubMed ID: 24794258
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The selective adhesion molecule inhibitor Natalizumab decreases multiple myeloma cell growth in the bone marrow microenvironment: therapeutic implications.
    Podar K; Zimmerhackl A; Fulciniti M; Tonon G; Hainz U; Tai YT; Vallet S; Halama N; Jäger D; Olson DL; Sattler M; Chauhan D; Anderson KC
    Br J Haematol; 2011 Nov; 155(4):438-48. PubMed ID: 21923653
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The CXCL12gamma chemokine immobilized by heparan sulfate on stromal niche cells controls adhesion and mediates drug resistance in multiple myeloma.
    Ren Z; Lantermans H; Kuil A; Kraan W; Arenzana-Seisdedos F; Kersten MJ; Spaargaren M; Pals ST
    J Hematol Oncol; 2021 Jan; 14(1):11. PubMed ID: 33436043
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The NF-kappaB inhibitor LC-1 has single agent activity in multiple myeloma cells and synergizes with bortezomib.
    Walsby EJ; Pratt G; Hewamana S; Crooks PA; Burnett AK; Fegan C; Pepper C
    Mol Cancer Ther; 2010 Jun; 9(6):1574-82. PubMed ID: 20515939
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Blockade of SDF-1/CXCR4 reduces adhesion-mediated chemoresistance of multiple myeloma cells via interacting with interleukin-6.
    Liu Y; Liang HM; Lv YQ; Tang SM; Cheng P
    J Cell Physiol; 2019 Nov; 234(11):19702-19714. PubMed ID: 30953364
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Targeting the Fanconi anemia/BRCA pathway circumvents drug resistance in multiple myeloma.
    Yarde DN; Oliveira V; Mathews L; Wang X; Villagra A; Boulware D; Shain KH; Hazlehurst LA; Alsina M; Chen DT; Beg AA; Dalton WS
    Cancer Res; 2009 Dec; 69(24):9367-75. PubMed ID: 19934314
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bortezomib-resistant nuclear factor-kappaB activity in multiple myeloma cells.
    Markovina S; Callander NS; O'Connor SL; Kim J; Werndli JE; Raschko M; Leith CP; Kahl BS; Kim K; Miyamoto S
    Mol Cancer Res; 2008 Aug; 6(8):1356-64. PubMed ID: 18708367
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Targeting MEK induces myeloma-cell cytotoxicity and inhibits osteoclastogenesis.
    Tai YT; Fulciniti M; Hideshima T; Song W; Leiba M; Li XF; Rumizen M; Burger P; Morrison A; Podar K; Chauhan D; Tassone P; Richardson P; Munshi NC; Ghobrial IM; Anderson KC
    Blood; 2007 Sep; 110(5):1656-63. PubMed ID: 17510321
    [TBL] [Abstract][Full Text] [Related]  

  • 37. TACI expression is associated with a mature bone marrow plasma cell signature and C-MAF overexpression in human myeloma cell lines.
    Moreaux J; Hose D; Jourdan M; Reme T; Hundemer M; Moos M; Robert N; Moine P; De Vos J; Goldschmidt H; Klein B
    Haematologica; 2007 Jun; 92(6):803-11. PubMed ID: 17550853
    [TBL] [Abstract][Full Text] [Related]  

  • 38. SDF-1 inhibition targets the bone marrow niche for cancer therapy.
    Roccaro AM; Sacco A; Purschke WG; Moschetta M; Buchner K; Maasch C; Zboralski D; Zöllner S; Vonhoff S; Mishima Y; Maiso P; Reagan MR; Lonardi S; Ungari M; Facchetti F; Eulberg D; Kruschinski A; Vater A; Rossi G; Klussmann S; Ghobrial IM
    Cell Rep; 2014 Oct; 9(1):118-128. PubMed ID: 25263552
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Induction therapy in a multiple myeloma mouse model using a combination of AS101 and melphalan, and the activity of AS101 in a tumor microenvironment model.
    Hayun M; Saida H; Albeck M; Peled A; Haran-Ghera N; Sredni B
    Exp Hematol; 2009 May; 37(5):593-603. PubMed ID: 19375650
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Romidepsin overcomes cell adhesion-mediated drug resistance in multiple myeloma cells.
    Sripayap P; Nagai T; Hatano K; Kikuchi J; Furukawa Y; Ozawa K
    Acta Haematol; 2014; 132(1):1-4. PubMed ID: 24356056
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.